机构:[1]Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China[2]Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[3]Central Hospital Affiliated to Shandong First Medical University, Jinan, China[4]Clinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[5]Respiratory Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China河南省肿瘤医院[6]The First Hospital of China Medical University, Shenyang, China[7]Beijing Chest Hospital, Capital Medical University, Beijing, China[8]The Affiliated Cancer Hospital of Xinjiang Medical University, Wulumuqi, China[9]Shanxi Cancer Hospital, Taiyuan, China[10]Second Affiliated Hospital of Nanchang University, Nanchang, China[11]The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China中山大学附属第一医院[12]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[13]Peking University Third Hospital, Beijing, China[14]Hunan Cancer Hospital, Changsha, China[15]The Affiliated Hospital of Inner Mongolia Medical University, Huhehaote, China[16]Chongqing Cancer Hospital, Chongqing, China[17]Department of Oncology, Jilin Cancer Hospital, Changchun, China[18]The First Affiliated Hospital, Zhejiang University School of Medicine, Hang Zhou, China浙江大学医学院附属第一医院[19]Army Medical Center of PLA, Chongqing, China[20]Dizal Pharmaceutical, Shanghai, China
第一作者机构:[1]Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
推荐引用方式(GB/T 7714):
Wang Mengzhao,Fan Yun,Sun Meili,et al.Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA:
Wang, Mengzhao,Fan, Yun,Sun, Meili,Wang, Yongsheng,Zhao, Yanqiu...&Zheng, Li.(2023).Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA:
Wang, Mengzhao,et al."Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)